Last C$0.06 CAD
Change Today 0.00 / 0.00%
Volume 1.3M
SL On Other Exchanges
Symbol
Exchange
Venture
Frankfurt
As of 10:18 AM 04/21/14 All times are local (Market data is delayed by at least 15 minutes).

supreme pharmaceuticals inc (SL) Snapshot

Open
C$0.06
Previous Close
C$0.05
Day High
C$0.06
Day Low
C$0.05
52 Week High
04/14/14 - C$0.09
52 Week Low
04/30/13 - C$0.0050
Market Cap
7.0M
Average Volume 10 Days
8.7M
EPS TTM
C$-0.01
Shares Outstanding
128.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SUPREME PHARMACEUTICALS INC (SL)

Related News

No related news articles were found.

supreme pharmaceuticals inc (SL) Related Businessweek News

No Related Businessweek News Found

supreme pharmaceuticals inc (SL) Details

Supreme Pharmaceuticals Inc., a junior exploration mining company, is engaged in the acquisition and development of mining properties in Canada. The company holds interests in the Ample-Goldmax property located in Lillooet, British Columbia; and the TAS project located in the Copper Mountain Mining Camp, near Princeton, British Columbia. It also has 100% interest in three mineral claims located in the Similkameen Mining Division of British Columbia; and six mineral claims situated in south Princeton, British Columbia. The company was formerly known as Supreme Resources Ltd. and changed its name to Supreme Pharmaceuticals Inc. in February 2014. Supreme Pharmaceuticals Inc. was incorporated in 1979 and is based in Coquitlam, Canada.

Founded in 1979

supreme pharmaceuticals inc (SL) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

supreme pharmaceuticals inc (SL) Key Developments

Supreme Pharmaceuticals To Delist From TSXV

Effective at the close of business on April 17, 2014 the common shares of Supreme Pharmaceuticals Inc. will be delisted from TSX Venture Exchange (TSXV) at the request of the Company. The Company will continue to trade on the Canadian Securities Exchange beginning April 21, 2014.

Supreme Extends Due Diligence

Supreme Pharmaceuticals Inc. (TSXV:SL) reports that the parties to the agreement to acquire the South Okanagan producing medical marijuana facility, have mutually agreed upon an extension of the due diligence period to April 29, 2014.

Supreme Pharmaceuticals In Discussion To Acquire Marijuana Producer

Supreme Pharmaceuticals Inc. (TSXV:SL) is planning for acquisitions. The company has entered into negotiations with a producing medical marijuana facility to acquire that business. President and Chief Executive Officer, David Stadnyk stated, "Our goal is to secure several medical marijuana producing facilities, each with a MMPR licence. There is no assurance that we will be able to secure such facilities. This is a critical year for MMPR licences and we plan on making several applications to Health Canada.”

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SL:CN C$0.06 CAD 0.00

SL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SL.
View Industry Companies
 

Industry Analysis

SL

Industry Average

Valuation SL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 135.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SUPREME PHARMACEUTICALS INC, please visit www.supremeresourcesltd.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.